Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel anti-CXCR4 antibody and its use for the detection and diagnosis of cancer

An antibody, CDR-H1 technology, applied in anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, antitumor drugs, measuring devices, etc., can solve the problem of tumor growth and angiogenesis having no effect

Inactive Publication Date: 2014-05-28
PIERRE FABRE MEDICAMENT SAS
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Another study (Phillips R.J et al., 2003) using a polyclonal antibody against SDF-1 also showed that the SDF-1 / CXCR4 axis plays a decisive role in the metastasis of an orthotopic lung cancer model (A549), but in this study, its No effect on tumor growth or angiogenesis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel anti-CXCR4 antibody and its use for the detection and diagnosis of cancer
  • Novel anti-CXCR4 antibody and its use for the detection and diagnosis of cancer
  • Novel anti-CXCR4 antibody and its use for the detection and diagnosis of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0292] Example 1: Production of anti-CXCR4427aB1 monoclonal antibody (Mab) (F50067-006(5C)427aB1 cl1B, CNCM number I-4018)

[0293] To generate monoclonal antibodies against CXCR4, Balb / c mice were immunized with recombinant NIH3T3-CXCR4 cells and / or peptides corresponding to the N-terminus and loop of CXCR4 cells. In the first immunization, mice aged 6-16 weeks are immunized subcutaneously (sc) with the antigen in complete Freund’s adjuvant, and then immunized with antigen sc in incomplete Freund’s adjuvant for 2 to 6 Times. Immune response was monitored by bleeding after the orbit. The serum was screened by ELISA (as described below), and mice with higher titers of anti-CXCR4 antibodies were used for fusion. Two days before sacrifice and spleen excision, mice were boosted intravenously with antigen.

[0294] -ELISA

[0295] To select mice that produce anti-CXCR4 antibodies, sera from immunized mice were tested by ELISA. In short, a microtiter plate was coated with purified [1-...

Embodiment 2

[0298] Example 2: 427aB1 monoclonal antibody recognizes both CXCR4 monomer and homodimer in cell lysate

[0299] Wash NIH3T3-hCXCR4 transfected cells, MDA-MB-231 (breast) and U937 (AML) cancer cells twice in PBS. Use the following buffer: 20mM TrisHCl pH8.5, 100mM(NH 4 ) 2 SO 4 , 10% glycerol, 1% CHAPSO and 1% protease inhibitor mixture will be 100.10 6 Cells / ml were lysed for 30 minutes. The cell lysate was collected by centrifugation at 10000 g at +4°C for 20 minutes and analyzed by western blotting with 427aB1 monoclonal antibody as the primary antibody. figure 1 It was shown that mAb 427aB1 recognizes both CXCR4 monomer and homodimer on NIH3T3-CXCR4. The cancer cell lines MDA-MB-231 and U937 seem to express CXCR4, which is mainly homodimer.

Embodiment 3

[0300] Example 3: 427aB1 monoclonal antibody immunoprecipitation of both CXCR4 monomer and homodimer

[0301] Use pH8.5 containing 100mM (NH4) 2 SO 4 Wash the NIH3T3-CXCR4 cell pellet with 20mM Tris HCl, and then resuspend it in the lysis buffer (20mM TrisHCl, pH8.5, containing 100mM(NH4) 2 SO 4 , 10% glycerol, 1% CHAPSO and a mixture of 10 μL / mL protease inhibitor). The cells were disrupted using a Potter Elvehjem homogenizer. The dissolved membrane was collected by centrifugation at 105000g at +4°C for 1 hour, and then incubated with Sepharose 4B beads conjugated with 427aB1 monoclonal antibody at +4°C overnight, the mixture was poured into a glass column and washed with lysis buffer. The protein captured by the 427aB1 monoclonal antibody was eluted and analyzed by western blotting with the anti-427aB1 monoclonal antibody as the primary antibody. Combine and concentrate the target fractions and use them for WB analysis and preparative SDS-PAGE resolution (4-12% Bis-Tris gel). ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a novel, isolated anti-CXCR4 antibody for use in the diagnosis of cancer. In particular, the antibody of the invention recognizes monomeric and homodimeric CXCR4, but not heterodimeric CXCR4

Description

Technical field [0001] The present invention relates to the field of prognosis and / or diagnosis and / or therapy monitoring of proliferative diseases in patients. More specifically, the present invention relates to antibodies capable of specifically binding to CXCR4, as well as amino acid and nucleic acid sequences encoding the antibodies. The present invention also includes the use of the antibody for detecting and diagnosing pathological hyperproliferative oncogenic disorders related to CXCR4 expression, and corresponding methods. In certain embodiments, the disease is an oncogenic disease associated with increased expression of CXCR4 relative to normal, or any other pathology associated with CXCR4 overexpression. The present invention ultimately includes products and / or compositions or kits containing at least such antibodies for the prognosis or diagnosis or treatment monitoring of certain cancers. Background technique [0002] Chemokines are small secretory peptides, which c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28
CPCC07K16/2866C07K2317/30C07K2317/565A61P35/00C07K16/2896G01N33/574C07K2317/51C07K2317/515G01N33/5748G01N2333/7158
Inventor C·克林格-哈默A·茹阿诺M-C·贾宁-比萨
Owner PIERRE FABRE MEDICAMENT SAS